TPMC guarantees a First-to-Market blockbuster product; Clopidogrel, as it was the first and only company to register this branded generic product in the segment of ADP receptor antagonists.
“Alendronate “another blockbuster branded generic was registered in the segment of Osteoporosis. The combined market value of these two therapeutic segments stands at nearly $19.2 million in the private & LPO segments of the Saudi market.